Sugi Predict

Sugi Predict / Compounds / SCHEMBL1955558

SCHEMBL1955558

SCHEMBL1955558

OCc1cc(Cl)c(Cl)cc1CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 1/20 0.40
▸ GRIA2 P42262 1/20 0.40
▸ GRIA3 P42263 1/20 0.40
▸ GRIA4 P48058 1/20 0.40
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ HSD17B10 Q99714 5/20 0.38
▸ HPGD P15428 3/20 0.38
▸ TSHR P16473 3/20 0.38
▸ AHR P35869 3/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PDXK O00764 1/20 0.34
▸ FLT1 P17948 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ RECQL P46063 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ CASP6 P55212 1/20 0.32
▸ CYP3A4 P08684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9567411 0.88 HSD17B10 (0.41) GRIA1GRIA2GRIA3GRIA4PDE4A
SCHEMBL522652 0.87 CBFB (0.36) GRIA1GRIA2GRIA3GRIA4PDE4A
SCHEMBL1903236 0.83 HSD17B10 (0.50) HSD17B10HPGDTSHRPDXKMAPT
SCHEMBL31618915 0.81 RAB9A (0.35) HSD17B10HPGDTSHRPDXKMAPT
SCHEMBL13696620 0.81 CD44 (0.42) GRIA1GRIA2GRIA3GRIA4PDE4A
SCHEMBL2662782 0.81 SHBG (0.43) PDE4APDE4BPDE4CPDE4DHSD17B10
SCHEMBL18133874 0.81 RAB9A (0.35) HSD17B10HPGDTSHRPDXKMAPT
SCHEMBL3367771 0.81 AHR (0.36) HSD17B10HPGDTSHRAHR
SCHEMBL16181881 0.81 GAA (0.46) HSD17B10HPGDTSHRAHRMAPK1
SCHEMBL672601 0.78 GRIA1 (0.48) GRIA1GRIA2GRIA3GRIA4PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171085-A Rhamnose donor protected by orthocarbonate, and preparation method and application thereof 山东大学 2020-05-19 — — CN claimed
WO-2025106910-A1 DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR FLARE THERAPEUTICS INC. (US) 2025-05-22 — — WO disclosed
US-20250092020-A1 IDO/TDO Inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-03-20 — — US disclosed
US-12209079-B2 IDO/TDO inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-01-28 — — US disclosed
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO HEALTH, INC. (US) 2024-03-05 — — US disclosed
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 — — WO disclosed
US-20220380305-A1 IDO/TDO Inhibitor CANBAS CO., LTD. 2022-12-01 — — US disclosed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 — — US disclosed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 — — US disclosed
US-20020082260-A1 Isoindolin-1-one glucokinase activators GUERTIN KEVIN RICHARD (US) 2002-06-27 — — US disclosed
WO-2002048106-A2 ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA-ROCHE AG (CH) 2002-06-20 — — WO disclosed
EP-0634401-B1 MDR reversal agents AMERICAN CYANAMID CO (US) 1997-08-13 — — EP disclosed
US-5639887-A MULTIDRUG RESISTANT CELLS; INCREASE CELL SENSITIVITY TO ANTICANCER AGENTS AMERICAN CYANAMID COMPANY (US) 1997-06-17 — — US disclosed
US-5561141-A POTENTIATE ACTIVITY OF ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY (US) 1996-10-01 — — US disclosed
US-5550149-A SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS AMERICAN CYANAMID COMPANY (US) 1996-08-27 — — US disclosed
US-5395827-A Analgesic, anticonvulsant, antiepileptic and anxiolytic agents GUILFORD PHARMACEUTICALS INC. (US) 1995-03-07 — — US disclosed
US-5387685-A MDR reversal agents AMERICAN CYANAMID COMPANY 1995-02-07 — — US disclosed
EP-0634401-A1 MDR reversal agents AMERICAN CYANAMID COMPANY (US) 1995-01-18 — — EP disclosed
WO-1993005772-A1 φ-[2-(PHOSPHONOALKYL)PHENYL]-2-AMINOALKANOIC ACIDS AS ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS NOVA PHARMACEUTICAL CORPORATION (US) 1993-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209079-B2 IDO/TDO inhibitor IDO1, IDO2, TDO2 GRIA1 1090/4885GRIA2 905/4885GRIA3 1483/4885
US-20020082260-A1 Isoindolin-1-one glucokinase activators GCKR, GCK, PGK2 GRIA1 1526/4885GRIA2 820/4885GRIA3 2333/4885
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 GRIA1 2078/4885GRIA2 2835/4885GRIA3 2570/4885
US-20250092020-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 GRIA1 1090/4885GRIA2 905/4885GRIA3 1483/4885
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 GRIA1 2078/4885GRIA2 2835/4885GRIA3 2570/4885
US-20220380305-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 GRIA1 758/4885GRIA2 841/4885GRIA3 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.